Overview
| 别名 | CCAAT/enhancer-binding protein alpha; C/EBP alpha |
| 基因名 | CEBPA |
| UniProt ID | P49715 |
| 反应种属 | Human |
| 应用 | WB,IP,CHIP |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 2H5-H5-R9 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 37 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | WB-1:2000; IP-1:100; CHIP-1:100 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | CCAAT enhancer binding protein alpha (CEBPA) is an intronless gene encoding a basic leucine zipper (bZIP) transcription factor that regulates gene expression by binding CCAAT-containing promoter elements as homodimers or heterodimers. Highly expressed in myeloid progenitors, adipocytes, and hepatocytes, CEBPA coordinates cell-cycle arrest and terminal differentiation by repressing E2F1 and interacting with the SWI/SNF complex. It is essential for granulocyte and monocyte lineage commitment, adipogenesis, and hepatic glucose and lipid metabolism. Mutations in CEBPA, particularly those affecting the N-terminal transactivation or C-terminal bZIP domains, impair DNA binding and block myeloid differentiation. Such mutations are a hallmark of a distinct subtype of acute myeloid leukemia (AML), which is recognized as a specific clinical entity often associated with a favorable prognosis. |
检测原理